PT2958916T - Formas sólidas de um inibidor de cdk4/6 seletivo - Google Patents

Formas sólidas de um inibidor de cdk4/6 seletivo

Info

Publication number
PT2958916T
PT2958916T PT14705884T PT14705884T PT2958916T PT 2958916 T PT2958916 T PT 2958916T PT 14705884 T PT14705884 T PT 14705884T PT 14705884 T PT14705884 T PT 14705884T PT 2958916 T PT2958916 T PT 2958916T
Authority
PT
Portugal
Prior art keywords
inhibitor
solid forms
selective cdk4
cdk4
selective
Prior art date
Application number
PT14705884T
Other languages
English (en)
Portuguese (pt)
Inventor
Patrick Chekal Brian
D Ide Nathan
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50151343&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2958916(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of PT2958916T publication Critical patent/PT2958916T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PT14705884T 2013-02-21 2014-02-08 Formas sólidas de um inibidor de cdk4/6 seletivo PT2958916T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361767761P 2013-02-21 2013-02-21

Publications (1)

Publication Number Publication Date
PT2958916T true PT2958916T (pt) 2018-11-21

Family

ID=50151343

Family Applications (2)

Application Number Title Priority Date Filing Date
PT14705884T PT2958916T (pt) 2013-02-21 2014-02-08 Formas sólidas de um inibidor de cdk4/6 seletivo
PT181866757T PT3431475T (pt) 2013-02-21 2014-02-08 Formas sólidas de um inibidor de cdk4/6 seletivo

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT181866757T PT3431475T (pt) 2013-02-21 2014-02-08 Formas sólidas de um inibidor de cdk4/6 seletivo

Country Status (24)

Country Link
US (2) US20160002223A1 (https=)
EP (2) EP3431475B1 (https=)
JP (3) JP6381016B2 (https=)
KR (2) KR20150107872A (https=)
CN (3) CN107759594A (https=)
AR (1) AR094842A1 (https=)
AU (1) AU2014220354B2 (https=)
BR (1) BR112015019508A8 (https=)
CA (1) CA2900322C (https=)
CY (2) CY1120734T1 (https=)
DK (2) DK3431475T3 (https=)
ES (2) ES2869277T3 (https=)
HK (2) HK1211032A1 (https=)
HU (2) HUE054212T2 (https=)
IL (1) IL240277B (https=)
MX (2) MX386473B (https=)
PL (2) PL3431475T3 (https=)
PT (2) PT2958916T (https=)
RU (1) RU2619944C2 (https=)
SG (1) SG11201505680RA (https=)
SI (2) SI3431475T1 (https=)
TR (1) TR201816077T4 (https=)
TW (2) TWI633103B (https=)
WO (1) WO2014128588A1 (https=)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201500125QA (en) 2012-07-11 2015-02-27 Blueprint Medicines Corp Inhibitors of the fibroblast growth factor receptor
MX386473B (es) 2013-02-21 2025-03-18 Pfizer Formas solidas de un inhibidor de cdk4/6 selectivo
RS63405B1 (sr) 2013-10-25 2022-08-31 Blueprint Medicines Corp Inhibitori receptora faktora rasta fibroblasta
US9695165B2 (en) 2014-01-15 2017-07-04 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
WO2016024249A1 (en) * 2014-08-14 2016-02-18 Sun Pharmaceutical Industries Limited Crystalline forms of palbociclib
WO2016030439A1 (en) * 2014-08-28 2016-03-03 Ratiopharm Gmbh Method of producing palbociclib and pharmaceutical compositions comprising the same
CN105616418A (zh) * 2014-11-07 2016-06-01 江苏豪森药业集团有限公司 含有细胞周期蛋白抑制剂的药物制剂及其制备方法
WO2016090257A1 (en) * 2014-12-05 2016-06-09 Crystal Pharmatech Inc. Salts and crystalline forms of 6-acetyl-8-cyclopentyl-5-methyl-2((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d] pyrimidin-7(8h)-one (palbociclib)
WO2016092442A1 (en) * 2014-12-08 2016-06-16 Sun Pharmaceutical Industries Limited Processes for the preparation of crystalline forms of palbociclib acetate
CN104610254B (zh) * 2015-01-26 2017-02-01 新发药业有限公司 一种帕博赛布的低成本制备方法
CZ201589A3 (cs) 2015-02-11 2016-08-24 Zentiva, K.S. Pevné formy soli Palbociclibu
WO2016156070A1 (en) 2015-04-02 2016-10-06 Sandoz Ag Modified particles of palbociclib
EP3078663A1 (en) 2015-04-09 2016-10-12 Sandoz Ag Modified particles of palbociclib
CN106117199A (zh) * 2015-05-04 2016-11-16 江苏恒瑞医药股份有限公司 一种细胞周期蛋白依赖性激酶抑制剂的二羟乙基磺酸盐、其结晶形式及其制备方法
KR102369405B1 (ko) * 2015-06-04 2022-03-02 화이자 인코포레이티드 팔보시클립의 고체 투여 형태
CN106317053A (zh) * 2015-06-29 2017-01-11 北大方正集团有限公司 一种帕博昔布晶型a的制备方法
CN106397431A (zh) * 2015-07-28 2017-02-15 苏州国匡医药科技有限公司 一种抗肿瘤药物的新晶型及其制备方法和用途
CN105153149B (zh) * 2015-07-29 2017-09-19 江苏中邦制药有限公司 一种选择性激酶抑制剂Palbociclib的制备方法
SI3331881T1 (sl) 2015-08-05 2019-08-30 Ratiopharm Gmbh Nova kristalna oblika in adukti palbocikliba in matanojske kisline
CN105085517B (zh) * 2015-08-06 2016-11-23 天津华洛康生物科技有限公司 一种结晶型帕博西尼游离碱水合物及其制备方法
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
SG10201913990RA (en) 2015-10-16 2020-03-30 Abbvie Inc PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
US11773106B2 (en) 2015-10-16 2023-10-03 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
CN106608876B (zh) * 2015-10-21 2018-06-19 新发药业有限公司 一种高纯度帕博西尼的制备方法
HU230962B1 (hu) 2015-10-28 2019-06-28 Egis Gyógyszergyár Zrt. Palbociclib sók
CN106632311B (zh) * 2015-11-02 2021-05-18 上海科胜药物研发有限公司 一种帕博西尼晶型a和晶型b的制备方法
CN106831759A (zh) * 2015-12-03 2017-06-13 上海星泰医药科技有限公司 帕布昔利布及其中间体的制备方法
CN105541832A (zh) * 2015-12-15 2016-05-04 南京艾德凯腾生物医药有限责任公司 一种羟乙基磺酸盐帕布昔利布的制备方法
WO2017115315A1 (en) * 2015-12-30 2017-07-06 Dr. Reddy's Laboratories Limited Solid forms of palbociclib
CN105524059A (zh) * 2016-01-06 2016-04-27 北京修正创新药物研究院有限公司 一种帕波西比杂质的制备方法
WO2017130219A1 (en) 2016-01-25 2017-08-03 Mylan Laboratories Limited Amorphous solid dispersion of palbociclib
GB201601329D0 (en) 2016-01-25 2016-03-09 Mohammad Mohammad A Inverse gas chromatography standard solutions, device and method
WO2017145054A1 (en) * 2016-02-24 2017-08-31 Lupin Limited Modified particles of crystalline palbociclib free base and process for the preparation thereof
CN105816437B (zh) 2016-03-29 2018-08-03 深圳市药欣生物科技有限公司 一种帕布昔利布的药物制剂及其制备方法
CN106336411B (zh) * 2016-04-27 2018-03-06 上海医药集团股份有限公司 Cdk4/6抑制剂帕博西尼高纯度原料药的制备工艺及用途
WO2017197904A2 (zh) * 2016-05-08 2017-11-23 上海诚妙医药科技有限公司 帕布昔利布的新晶型及其制备方法及其用途
CN105924439B (zh) * 2016-06-24 2017-11-24 石家庄海瑞药物科技有限公司 一种帕布昔利布的制备方法
CN106146494B (zh) * 2016-06-29 2018-02-06 重庆华邦制药有限公司 用于制备帕布昔利布a型晶的溶剂及制备方法
MX2019000246A (es) 2016-07-07 2019-05-27 Plantex Ltd Formas en estado solido del dimesilato de palbociclib.
CN106220627A (zh) * 2016-07-31 2016-12-14 合肥远志医药科技开发有限公司 一种高纯度帕布昔利布的工业化制备方法
CN106220626A (zh) * 2016-07-31 2016-12-14 合肥远志医药科技开发有限公司 一种帕布昔利布的多晶型及其制备方法
PT3497103T (pt) 2016-08-15 2021-06-17 Pfizer Inibidores de piridopirimidinona cdk2/4/6
WO2018049233A1 (en) 2016-09-08 2018-03-15 Nicolas Stransky Inhibitors of the fibroblast growth factor receptor in combination with cyclin-dependent kinase inhibitors
WO2018065999A1 (en) 2016-10-07 2018-04-12 Mylan Laboratories Limited Novel polymorph of an intermediate for palbociclib synthesis
WO2018073574A1 (en) 2016-10-20 2018-04-26 Cipla Limited Polymorphic forms of palbociclib
US10849903B2 (en) * 2016-10-20 2020-12-01 Pfizer Inc. Anti-proliferative agents for treating PAH
CN108017630B (zh) * 2016-10-31 2022-10-11 上海创诺制药有限公司 一种小比表面积帕博西尼游离碱的制备方法
US20190275049A1 (en) 2016-11-16 2019-09-12 Pfizer Inc. Combination of an EGFR T790M Inhibitor and a CDK Inhibitor for the Treatment of Non-Small Cell Lung Cancer
CN108117550B (zh) * 2016-11-29 2020-08-14 上海医药工业研究院 吡啶并[2,3-d]嘧啶类化合物的制备方法
TWI749126B (zh) 2016-12-16 2021-12-11 大陸商基石藥業（蘇州）有限公司 Cdk4/6抑制劑
CN110573183A (zh) * 2017-04-21 2019-12-13 上海方楠生物科技有限公司 一种帕博西林组合物及其制备方法
CN108864078B (zh) * 2017-05-10 2021-10-15 江苏豪森药业集团有限公司 帕博西尼晶型b的制备方法
EP3652318A1 (en) 2017-07-11 2020-05-20 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
US11529353B2 (en) 2017-07-28 2022-12-20 Synthon B.V. Pharmaceutical composition comprising Palbociclib
MX2020001875A (es) 2017-08-18 2020-07-29 Tragara Pharmaceuticals Inc Forma polimorfica de tg02.
CN111386272B (zh) 2017-10-27 2023-01-06 费森尤斯卡比肿瘤学有限公司 一种改进的瑞博西尼及其盐的制备方法
CN109897034A (zh) * 2017-12-07 2019-06-18 南京卡文迪许生物工程技术有限公司 一种高纯度晶型a帕布昔利布及其制备方法和药物组合物
EP3738084A4 (en) 2018-01-08 2021-11-17 G1 Therapeutics, Inc. SUPERIOR G1T38 DOSING SCHEMES
CN108586452A (zh) * 2018-01-12 2018-09-28 重庆市碚圣医药科技股份有限公司 一种帕博西尼中间体的合成方法
EP3758753A1 (en) 2018-02-27 2021-01-06 Pfizer Inc Combination of a cyclin dependent kinase inhibitor and a bet-bromodomain inhibitor
CN108299422B (zh) * 2018-02-28 2019-10-25 杭州福斯特药业有限公司 一种帕泊昔利布中间体的制备方法
EP4309656A3 (en) 2018-05-14 2024-02-28 Pfizer Inc. Oral solution formulation
CN108558745A (zh) * 2018-05-17 2018-09-21 苏州莱克施德药业有限公司 一种帕博西林中间体的合成方法
WO2019224194A1 (en) 2018-05-24 2019-11-28 Synthon B.V. A process for making palbociclib
WO2019238088A1 (zh) * 2018-06-13 2019-12-19 基石药业 吡啶并吡啶酮衍生物的盐型及晶型
US11242528B2 (en) 2018-08-28 2022-02-08 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
JP6952747B2 (ja) 2018-09-18 2021-10-20 ファイザー・インク がん処置のためのＴＧＦβ阻害剤およびＣＤＫ阻害剤の組合せ
CN113286592A (zh) 2018-10-24 2021-08-20 效应治疗股份有限公司 Mnk抑制剂的结晶形式
CN109336886A (zh) * 2018-12-07 2019-02-15 重庆三圣实业股份有限公司 一种帕博西尼的制备方法及其产品
AU2020209500B2 (en) * 2019-01-17 2022-08-25 Pfizer Inc. Crystalline form of a CDK inhibitor
WO2020157709A1 (en) 2019-02-01 2020-08-06 Pfizer Inc. Combination of a cdk inhibitor and a pim inhibitor
WO2020239558A1 (en) 2019-05-24 2020-12-03 Pfizer Inc. Combination therapies using cdk inhibitors
CA3141452A1 (en) 2019-05-24 2020-12-03 Pfizer Inc. Combination therapies using cdk inhibitors
CN110256424A (zh) * 2019-07-03 2019-09-20 武汉工程大学 一种帕博西尼关键中间体v的合成方法
KR20220054347A (ko) 2019-08-26 2022-05-02 아비나스 오퍼레이션스, 인코포레이티드 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 유도체로 유방암을 치료하는 방법
CN110551063A (zh) * 2019-10-17 2019-12-10 山东邹平大展新材料有限公司 一种合成5-(n-boc-哌嗪-1-基)吡啶-2-胺的方法
TW202146017A (zh) 2020-03-05 2021-12-16 美商輝瑞股份有限公司 間變性淋巴瘤激酶抑制劑及周期蛋白依賴型激酶抑制劑之組合
FI4181920T3 (fi) 2020-07-15 2025-11-20 Pfizer Kat6-estäjämenetelmät ja yhdistelmät syövän hoitoon
US20230321042A1 (en) 2020-07-20 2023-10-12 Pfizer Inc. Combination therapy
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法
WO2022091001A1 (en) 2020-10-29 2022-05-05 Pfizer Ireland Pharmaceuticals Process for preparation of palbociclib
CN112274493A (zh) * 2020-11-18 2021-01-29 石药集团中奇制药技术（石家庄）有限公司 一种哌柏西利胶囊的制备方法
CN112457311B (zh) * 2020-12-04 2022-07-12 江苏豪森药业集团有限公司 一种含有氯溴吡咯嘧啶酮结构化合物的制备方法
WO2022123419A1 (en) 2020-12-08 2022-06-16 Pfizer Inc. Treatment of luminal subtypes of hr-positive, her2-negative early breast cancer with palbociclib
CN112661753B (zh) * 2020-12-29 2022-06-03 山东铂源药业股份有限公司 一种帕布昔利布中间体的制备方法
CN112778303A (zh) * 2020-12-31 2021-05-11 武汉九州钰民医药科技有限公司 Cdk4/6激酶抑制剂shr6390的制备方法
CN112898299B (zh) * 2021-01-26 2021-11-26 山东铂源药业有限公司 一种帕布昔利布中间体的制备方法
EP4356398A4 (en) 2021-06-14 2025-04-16 Preh Holding, LLC CONNECTED BODY SURFACE CARE MODULE
CN117396208A (zh) 2021-07-16 2024-01-12 达纳－法伯癌症研究所公司 细胞周期蛋白依赖性激酶4/6(cdk4/6)和ikzf2(helios)的小分子降解剂及其使用方法
CN113845520A (zh) * 2021-09-09 2021-12-28 安徽皓元药业有限公司 一种帕布昔利布乳清酸盐及其制备方法
CN113999227A (zh) * 2021-11-26 2022-02-01 常州大学 一种帕博西尼中间体的制备方法
WO2023107525A1 (en) 2021-12-10 2023-06-15 Eli Lilly And Company Cdk4 and 6 inhibitor in combination with fulvestrant for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer in patients previously treated with a cdk4 and 6 inhibitor
US20250049802A1 (en) 2021-12-14 2025-02-13 Pfizer Inc. Combination therapies and uses for treating cancer
WO2023114264A1 (en) 2021-12-15 2023-06-22 Eli Lilly And Company Combination for treatment of high-risk metastatic hormone-sensitive prostate cancer
CN114195784A (zh) * 2021-12-29 2022-03-18 斯坦德标准技术研究(湖北)有限公司 帕博西尼有关物质及其制备方法和应用
EP4302832A1 (en) 2022-07-07 2024-01-10 Lotus Pharmaceutical Co., Ltd. Palbociclib formulation containing glucono delta lactone
EP4302755B1 (en) 2022-07-07 2025-08-20 Lotus Pharmaceutical Co., Ltd. Palbociclib formulation containing an amino acid
JP2025533719A (ja) 2022-07-29 2025-10-09 ファイザー・インク がんの治療のためのｋａｔ６阻害剤を含む投与レジメン
CN120112291A (zh) 2022-08-31 2025-06-06 阿尔维纳斯运营股份有限公司 雌激素受体降解剂的给药方案
CN120456897A (zh) 2022-11-02 2025-08-08 佩特拉制药公司 用于治疗疾病的磷酸肌醇3-激酶(pi3k)变构色原酮抑制剂
WO2024133726A1 (en) 2022-12-22 2024-06-27 Synthon B.V. Pharmaceutical composition comprising palbociclib
WO2024132652A1 (en) 2022-12-22 2024-06-27 Synthon B.V. Pharmaceutical composition comprising palbociclib
CN120981721A (zh) 2023-03-30 2025-11-18 辉瑞大药厂 Kat6a作为用kat6a抑制剂治疗的预测性生物标志物和相关治疗方法
WO2024201340A1 (en) 2023-03-30 2024-10-03 Pfizer Inc. Kat6a as a predictive biomarker for treatment of breast cancer with a cdk4 inhibitor and an antiestrogen and methods of treatment thereof
CN121843694A (zh) 2023-09-06 2026-04-10 阿费克斯发展有限公司 用于治疗及预防口腔癌的组合物与方法
WO2025122470A1 (en) 2023-12-04 2025-06-12 Genentech, Inc. Combination therapies for treatment of breast cancer
WO2025202854A1 (en) 2024-03-27 2025-10-02 Pfizer Inc. Cdk4 inhibitors and combinations with cdk2 inhibitors or further agents for use in the treatment of cancer
WO2026025013A2 (en) 2024-07-26 2026-01-29 Pfizer Inc. Combination therapy using cdk4 inhibitors for cancer treatments

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
JPH11138004A (ja) * 1997-11-06 1999-05-25 Mitsui Chem Inc ニトリル水和用の銅触媒及びその調製方法
AP2002002643A0 (en) * 2000-03-06 2002-12-31 Warner Lambert Co 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors
MXPA04005939A (es) 2002-01-22 2005-01-25 Warner Lambert Co 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas.
JP2004074041A (ja) * 2002-08-20 2004-03-11 Cabot Supermetal Kk フッ素の回収方法
JP2004149472A (ja) * 2002-10-31 2004-05-27 Sumitomo Chem Co Ltd 亜リン酸エステル類の結晶、及びその製造方法
AU2004255934B2 (en) * 2003-07-11 2010-02-25 Warner-Lambert Company Llc Isethionate salt of a selective CDK4 inhibitor
US7825138B2 (en) * 2004-06-29 2010-11-02 Helsinn Therapeutics (U.S.), Inc. Crystal forms of (3R)-1-(2-methylalanyl-D-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide
GT200600315A (es) * 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
BRPI0716880A2 (pt) * 2006-09-08 2013-10-15 Pfizer Prod Inc Síntese de 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas
WO2009019205A1 (en) * 2007-08-03 2009-02-12 Boehringer Ingelheim International Gmbh Crystalline form of a dihydropteridione derivative
TW201014830A (en) * 2008-09-30 2010-04-16 Theravance Inc Crystalline form of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid
KR101742252B1 (ko) * 2009-07-15 2017-05-31 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 비페닐 화합물의 결정질 유리 염기형
BR112012006252A2 (pt) * 2009-09-20 2017-05-23 Abbott Lab "formas cristalinas de abt-263 e solvatos para o uso no tratamento de doenças relacionadas á proteína bcl-2".
CZ201039A3 (cs) 2010-01-19 2011-07-27 Zentiva, K. S Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme
PH12013500934A1 (en) * 2010-11-09 2022-10-24 Zafgen Inc Crystalline solids of a metap-2 inhibitor and methods of making and using same
MX386473B (es) 2013-02-21 2025-03-18 Pfizer Formas solidas de un inhibidor de cdk4/6 selectivo
WO2016024249A1 (en) 2014-08-14 2016-02-18 Sun Pharmaceutical Industries Limited Crystalline forms of palbociclib

Also Published As

Publication number Publication date
EP2958916A1 (en) 2015-12-30
BR112015019508A2 (pt) 2017-07-18
ES2869277T3 (es) 2021-10-25
TW201444834A (zh) 2014-12-01
NZ710138A (en) 2020-09-25
JP2019116512A (ja) 2019-07-18
TWI633103B (zh) 2018-08-21
EP3431475A1 (en) 2019-01-23
CY1124068T1 (el) 2022-05-27
BR112015019508A8 (pt) 2019-11-19
JP2014162794A (ja) 2014-09-08
US20160002223A1 (en) 2016-01-07
HUE054212T2 (hu) 2021-08-30
EP3431475B1 (en) 2021-04-07
MX363715B (es) 2019-03-29
CN107759594A (zh) 2018-03-06
ES2694787T3 (es) 2018-12-27
RU2619944C2 (ru) 2017-05-22
JP2017186376A (ja) 2017-10-12
AR094842A1 (es) 2015-09-02
SI2958916T1 (sl) 2018-11-30
SI3431475T1 (sl) 2021-08-31
IL240277A0 (en) 2015-09-24
PL3431475T3 (pl) 2021-09-13
SG11201505680RA (en) 2015-09-29
CN111253394A (zh) 2020-06-09
KR101858913B1 (ko) 2018-05-16
MX386473B (es) 2025-03-18
US20180065964A1 (en) 2018-03-08
JP6524152B2 (ja) 2019-06-05
KR20170094012A (ko) 2017-08-16
AU2014220354B2 (en) 2018-02-01
DK2958916T3 (en) 2018-11-12
CN105008357A (zh) 2015-10-28
US10723730B2 (en) 2020-07-28
HK1211032A1 (en) 2016-05-13
MX2019003605A (es) 2019-06-17
TR201816077T4 (tr) 2018-11-21
DK3431475T3 (da) 2021-05-25
CA2900322C (en) 2019-03-26
CA2900322A1 (en) 2014-08-28
HUE040434T2 (hu) 2019-03-28
WO2014128588A1 (en) 2014-08-28
CY1120734T1 (el) 2019-12-11
MX2015010858A (es) 2015-12-03
PT3431475T (pt) 2021-05-13
PL2958916T3 (pl) 2019-01-31
HK1248217A1 (zh) 2018-10-12
IL240277B (en) 2019-10-31
EP2958916B1 (en) 2018-09-12
TW201803872A (zh) 2018-02-01
TWI670269B (zh) 2019-09-01
AU2014220354A1 (en) 2015-08-06
KR20150107872A (ko) 2015-09-23
JP6381016B2 (ja) 2018-08-29
RU2015132371A (ru) 2017-03-29

Similar Documents

Publication Publication Date Title
IL240277A0 (en) Solid forms of a selective inhibitor of cdk4/6
ZA201702252B (en) A selective inhibitor of prosphatidylinositol 3-kinase-gamma
EP2943204A4 (en) BETA-Lactamase INHIBITORS
IL252834A0 (en) A process for making a pde4 inhibitor
IL245442A0 (en) gsk–3 inhibitors
ZA201506156B (en) Novel inhibitors
GB201317609D0 (en) Inhibitor compounds
ZA201508940B (en) Inhibitor for retinochoroidal disorders
PL3027594T3 (pl) Pochodne 2-benzoilaminobenzamidu jako inhibitory bcl-3
SG11201509599QA (en) Pentosidine production inhibitor
IL245386A0 (en) A crystalline beta-lactamase inhibitor
GB201321328D0 (en) Inhibitor compounds
GB201305503D0 (en) Inhibitor
GB201307906D0 (en) Corrosion inhibitor
HK1227408A1 (en) A selective inhibitor of phosphatidylinositol 3-kinase-gamma
GB201308117D0 (en) Inhibitor of calcifying disorders